Vol.58 No.3, September 30, 2023
Fnu Aakash, Sa A Wang, Karan Saluja, Beenu Thakral
Blood Res 2023; 58(3): 125-125Jian Li, Merit Hanna
Blood Res 2023; 58(3): 126-126Mahnaz Yadollahi, Hessam Hosseinalipour, Mehrdad Karajizadeh, Muhammad Alinaqi, Pooria Fazeli, Mehrdad Jowkar, Kazem Jamali, Maryam Yadollahi
Blood Res 2023; 58(3): 127-132Abstract : Background
Pulmonary thromboembolism (PTE) is a significant contributing factor to vascular diseases. This study aimed to determine the prevalence of pulmonary thromboembolism and its predisposing factors in patients with COVID-19.
Methods
This cross-sectional study included 284 patients with COVID-19 who were admitted to Nemazee Teaching Hospital (Shiraz, Iran) between June and August 2021. All patients were diagnosed with COVID-19 by a physician based on clinical symptoms or positive polymerase chain reaction (PCR) test results. The collected data included demographic data and laboratory findings. Data were analyzed using the SPSS software. P≤0.05 was considered statistically significant.
Results
There was a significant difference in the mean age between the PTE group and non-PTE group (P=0.037). Moreover, the PTE group had a significantly higher prevalence of hypertension (36.7% vs. 21.8%, P=0.019), myocardial infarction (4.5% vs. 0%, P=0.006), and stroke (23.9% vs. 4.9%, P=0.0001). Direct bilirubin (P=0.03) and albumin (P=0.04) levels significantly differed between the PTE and non-PTE groups. Notably, there was a significant difference in the partial thromboplastin time (P=0.04) between the PTE and non-PTE groups. A regression analysis indicated that age (OR, 1.02; 95% CI, 1.00‒1.004; P=0.005), blood pressure (OR, 2.07; 95% CI, 1.12‒3.85; P=0.02), heart attack (OR, 1.02; 95% CI, 1.28‒6.06; P=0.009), and albumin level (OR, 0.39; 95% CI, 0.16‒0.97; P=0.04) were all independent predictors of PTE development.
Conclusion
Regression analysis revealed that age, blood pressure, heart attack, and albumin levels were independent predictors of PTE.
Seong-Ho Kang, Ji Seon Choi
Blood Res 2023; 58(3): 133-137Abstract : Background
Epigenetic studies, particularly research on microRNA (miRNA), have flourished. The abnormal expression of miRNA contributes to the development of hematologic malignancies. miR-765 has been reported to inhibit cell proliferation by downregulating proteolipid protein 2 (PLP2), which causes apoptosis. We investigated miR-765 dysregulation in myelodysplastic syndromes (MDS).
Methods
We compared the expression profiles of miR-765 in 65 patients with MDS and 11 controls. Cell proliferation and apoptosis assays were performed to determine the in vitro effects of miR-765 on leukemia cells transfected with the miR-765 mimic. Reverse transcription quantitative PCR (RT-qPCR) and western blotting were performed to examine the targets of miR-765.
Results
We found that miR-765 levels were upregulated 10.2-fold in patients with MDS compared to controls. In refractory cytopenia with multilineage dysplasia, the percentage of patients with elevated miR-765 levels was significantly higher than in other forms of MDS. Experiments with leukemia cells revealed that transfection with a miR-765 mimic inhibited cell proliferation and induced apoptosis. RT-qPCR and western blotting demonstrated that the target of miR-765 was PLP2.
Conclusion
These findings imply that upregulation of miR-765 induces apoptosis via downregulation of PLP2 and may have a role in MDS pathogenesis.
Alexander T. Phan, Ari A. Ucar, Aldin Malkoc, Janie Hu, Luke Buxton, Alan W. Tseng, Fanglong Dong, Julie P.T. Nguyễn, Arnav P. Modi, Ojas Deshpande, Johnson Lay, Andrew Ku, Dotun Ogunyemi, Sarkis Arabian
Blood Res 2023; 58(3): 138-144Abstract : Background
Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.
Methods
This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).
Results
The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (P<0.001). There was statistically significant association between combined ABO and RH blood type and mortality (P=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (P=0.005). The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.
Conclusion
ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.
Hyun Min Kim, Joonyeop Lee, Seokjin Kim, Jong Wook Lee, Hee-Je Kim, Young-Seok Cho
Blood Res 2023; 58(3): 145-148Ahmad Alshomrani, Jeffrey J. Cannatella, Hina Qureishi
Blood Res 2023; 58(3): 148-151Suji Park, Jae-Ryong Shim, Ji Hyun Lee, Jin-Yeong Han
Blood Res 2023; 58(3): 151-155Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Youngil Koh
Blood Res 2023; 58(3): 155-157Sadiq Khalaf Ali, Saad Abdulbaqi Alomar, Hussam Mahmood Salih, Nooran Salem Yaseen
Blood Res 2023; 58(3): 157-161Amiya Ranjan Nayak, Deepika Yadav, Priyanka Naranje, Jasmita Dass, Pradeep Kumar, Mukul Aggarwal
Blood Res 2023; 58(3): 161-163Nisha Marwah, Manali Satiza, Niti Dalal, Sudhir Atri, Monika Gupta, Sunita Singh, Rajeev Sen
Blood Res 2021;56: 26-30Junshik Hong, Seo-Yeon Ahn, Yoo Jin Lee, Ji Hyun Lee, Jung Woo Han, Kyoung Ha Kim, Ho-Young Yhim, Seung-Hyun Nam, Hee-Jin Kim, Jaewoo Song, Sung-Hyun Kim, Soo-Mee Bang, Jin Seok Kim, Yeung-Chul Mun, Sung Hwa Bae, Hyun Kyung Kim, Seongsoo Jang, Rojin Park, Hyoung Soo Choi, Inho Kim, Doyeun Oh; on behalf of the Korean Society of Hematology Thrombosis and Hemostasis Working Party
Blood Res 2021;56: 6-16Yu Ri Kim, Dae-Young Kim
Blood Res 2021;56: S17-S25Seyed Mohammad Sadegh Pezeshki, Najmadin Saki, Mehran Varnaseri Ghandali, Alireza Ekrami, Arshid Yousefi Avarvand
Blood Res 2021;56: 38-43+82-2-516-6582